Trial Profile
To Evaluate the Safety and Efficacy of Hunterase(Idursulfase-beta) in Hunter Syndrome Patients less than 6 Years of Age Receiving Idursulfase Enzyme Replacement Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Idursulfase (Primary)
- Indications Mucopolysaccharidosis II
- Focus Adverse reactions
- Sponsors GC Pharma; Green Cross
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma
- 24 Apr 2014 New trial record